Discover Charcot-Marie-Tooth Disease Type I a Therapeutic Pipeline H2 2016, Drug Profile and Major Key Players
Charcot-Marie-Tooth Disease Type I A Pipeline Review, H2 2016, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics. Charcot-Marie-Tooth Disease Type I A therapeutics industry report provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease Type I A, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action...
View full press release